Related Experiment Video
Updated: Aug 13, 2026
09:57
System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
Summary
Rifampin significantly reduces warfarin effectiveness, requiring higher doses for therapeutic anticoagulation. Stopping rifampin necessitates a substantial warfarin dose reduction to maintain safe and effective blood thinning.
Area of Science:
- Pharmacology
- Internal Medicine
- Drug Interactions
Background:
- Warfarin is a common anticoagulant used to prevent blood clots.
- Rifampin is an antibiotic frequently used to treat tuberculosis and other infections.
- Potential drug interactions between rifampin and warfarin can impact patient safety.
Purpose of the Study:
- To investigate the clinical impact of concurrent rifampin and warfarin administration.
- To quantify the effect of rifampin on warfarin dosage requirements for therapeutic anticoagulation.
Main Methods:
- A case study involving a 72-year-old male patient treated with both rifampin and warfarin.
- Monitoring of prothrombin time (PT) levels during concurrent therapy and after rifampin discontinuation.
- Adjustment of warfarin dosage to achieve and maintain therapeutic anticoagulation.
Main Results:
- Concurrent rifampin therapy necessitated a significantly higher warfarin dosage (20 mg daily) to achieve therapeutic anticoagulation.
- Upon rifampin cessation, warfarin dosage requirement decreased substantially (7.5 mg daily) to maintain therapeutic PT levels.
- A marked increase in PT was observed after discontinuing rifampin, indicating reduced warfarin metabolism.
Conclusions:
- Rifampin significantly induces warfarin metabolism, leading to reduced anticoagulant effect.
- Close monitoring of anticoagulation status and warfarin dosage adjustments are crucial when initiating or discontinuing rifampin in patients on warfarin.
- This interaction highlights the importance of considering concomitant medications in anticoagulation management.
More Related Videos
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:23Factors Affecting Protein-Drug Binding: Drug Interactions
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
01:26Pharmacokinetics: Drug–Food and Drug–Viral Interactions
A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...